In the November/December 2015 issue of PharmaVOICE, Rhett Johnson explains that to achieve better value, the health care industry must define what value looks like and measure how effectively it is being produced. To read the article, click here.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...